These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27417383)

  • 21. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
    Toth LA; Stevenson M; Chakravarthy U
    Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION.
    Takahashi H; Ohkubo Y; Sato A; Takezawa M; Fujino Y; Yanagi Y; Kawashima H
    Retina; 2015 Jul; 35(7):1331-8. PubMed ID: 25719984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration?
    Razavi H; Arnold J; Guymer R
    Clin Exp Ophthalmol; 2015 Nov; 43(8):707-10. PubMed ID: 26498270
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of repeated intravitreal bevacizumab injections on the inner retinal function in neovascular age-related macular degeneration.
    Kim HD; Kim SH; Cho IH; Moon CH; Ohn YH; Park TK
    Acta Ophthalmol; 2013 Mar; 91(2):e154-6. PubMed ID: 22989051
    [No Abstract]   [Full Text] [Related]  

  • 25. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy.
    Karaca EE; Kepez Yldz B; Çubuk MÖ; Özdek Ş
    Retina; 2015 Aug; 35(8):1540-6. PubMed ID: 25768251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200.
    Parodi MB; Cascavilla M; Papayannis A; Kontadakis DS; Bandello F; Iacono P
    Arch Ophthalmol; 2012 Jul; 130(7):934-5. PubMed ID: 22776937
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.
    Berg K; Pedersen TR; Sandvik L; Bragadóttir R
    Ophthalmology; 2015 Jan; 122(1):146-52. PubMed ID: 25227499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment.
    Charafeddin W; Nittala MG; Oregon A; Sadda SR
    Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):523-30. PubMed ID: 26057755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
    Mantel I; Gianniou C; Dirani A
    Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The TWIN Study.
    Souied EH; Oubraham H; Mimoun G; Cohen SY; Quere S; Derveloy A;
    Retina; 2015 Sep; 35(9):1743-9. PubMed ID: 25901835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranibizumab Versus Bevacizumab for Neovascular Age-Related Macular Degeneration With an Incomplete Posterior Vitreous Detachment.
    Rush RB; Rush SW
    Asia Pac J Ophthalmol (Phila); 2016 May; 5(3):171-5. PubMed ID: 26692256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixation stability and implication for multifocal electroretinography in patients with neovascular age-related macular degeneration after anti-VEGF treatment.
    Pedersen KB; Sjølie AK; Vestergaard AH; Andréasson S; Møller F
    Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):1897-1908. PubMed ID: 27080862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Choi KE; Hwang SY; Kim SW; Huh K
    BMC Ophthalmol; 2016 Mar; 16():25. PubMed ID: 26951107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05.
    Koch R; Schmidt M; Gebauer S; Busse H; Uhlig CE
    BMC Ophthalmol; 2015 Oct; 15():138. PubMed ID: 26490832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.